FMP
Arrowhead Pharmaceuticals Announced a Deal For a NASH Asset
Nov 24, 2021 1:40 AM - Davit Kirakosyan(Last modified: Dec 19, 2023 6:49 PM)
Image credit: FMP
Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) made an announcement, according to which they reached a deal with GSK for ARO-HSD, their lead asset for NASH. The company will receive a $120 million upfront payment, up to $910 million in downstream milestones and royalties up to 20%, while GSK will receive exclusive global rights in all territories, excluding China. Non-dilutive capital should extend the runway and allow the company to focus on wholly-owned programs, which analysts believe will have a higher ROI.
Other Blogs
May 14, 2024 11:41 AM - Sanzhi Kobzhan
The easiest way to calculate stock’s target price and why the target price is important.
A stock's target price, also known as its fair value, is an indication of what a share can cost based on the company’s forecasted financial statements. It is important to know a stock's fair value to find undervalued stocks with great growth potential. Let's consider how investment analysts calculat...
May 24, 2024 9:30 AM - Rajnish Katharotiya
How to Access and Analyze Earnings Call Transcripts
Earnings call transcripts are invaluable resources for investors, analysts, and financial enthusiasts. They provide insights into a company's performance, strategy, and future outlook, making them essential for making informed investment decisions. With Financial Modeling Prep, Earnings Call Transcr...
May 27, 2024 3:30 PM - Rajnish Katharotiya
The best 5 GPU stocks other than NVDA
In the ever-evolving world of technology, certain sectors have consistently demonstrated exceptional growth and innovation. The graphics processing units (GPUs) industry is one such sector, offering investors a golden opportunity for potentially high returns. In this blog, we'll delve into why inves...
